Regeneron Pharmaceuticals has entered a drug pricing agreement with the Trump administration, becoming the latest company to participate in the 'most favored nation' pricing program. The deal, announced on April 23, includes offering a new hearing-loss gene therapy for free to eligible U.S. patients following its FDA approval earlier that day.
Core Facts
Regeneron agreed to lower U.S. drug prices for some Americans as part of the deal, which also exempts the company from tariffs for three years. The FDA approved Regeneron's gene therapy, Otarmeni, which targets an ultra-rare genetic condition causing hearing loss. The therapy received expedited approval under the National Priority Voucher program and is expected to generate peak sales of $130 million, according to Piper Sandler analysts.
Deeper Dive & Context
The Trump administration has negotiated 17 such deals with pharmaceutical companies, aiming to tie U.S. drug prices to the lowest prices in other developed nations. Regeneron's agreement comes amid broader efforts to reduce drug costs, with the White House emphasizing the potential benefits for patients. The gene therapy, Otarmeni, has shown promise in restoring hearing in a small number of deaf children, marking a significant breakthrough for patients with genetic hearing loss.
Policy and Implications
The 'most favored nation' pricing model has been a key part of the Trump administration's strategy to lower drug costs. Companies that participate in the program are exempt from tariffs, including planned levies of up to 100% on some pharmaceutical products. The CMS deputy administrator, Chris Klomp, noted that more negotiations are underway with other biotech and pharma companies. The FDA's expedited approval process for Otarmeni highlights the agency's focus on addressing rare diseases and conditions with unmet medical needs.